These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 26234336)

  • 1. Memantine and reduced time with dyskinesia in Parkinson's Disease.
    Wictorin K; Widner H
    Acta Neurol Scand; 2016 May; 133(5):355-60. PubMed ID: 26234336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amantadine extended release for levodopa-induced dyskinesia in Parkinson's disease (EASED Study).
    Pahwa R; Tanner CM; Hauser RA; Sethi K; Isaacson S; Truong D; Struck L; Ruby AE; McClure NL; Went GT; Stempien MJ
    Mov Disord; 2015 May; 30(6):788-95. PubMed ID: 25650051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of memantine (NMDA antagonist) on Parkinson's disease: a double-blind crossover randomized study.
    Merello M; Nouzeilles MI; Cammarota A; Leiguarda R
    Clin Neuropharmacol; 1999; 22(5):273-6. PubMed ID: 10516877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.
    Fox SH; Metman LV; Nutt JG; Brodsky M; Factor SA; Lang AE; Pope LE; Knowles N; Siffert J
    Mov Disord; 2017 Jun; 32(6):893-903. PubMed ID: 28370447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease.
    Verhagen Metman L; Del Dotto P; van den Munckhof P; Fang J; Mouradian MM; Chase TN
    Neurology; 1998 May; 50(5):1323-6. PubMed ID: 9595981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
    Berg D; Godau J; Trenkwalder C; Eggert K; Csoti I; Storch A; Huber H; Morelli-Canelo M; Stamelou M; Ries V; Wolz M; Schneider C; Di Paolo T; Gasparini F; Hariry S; Vandemeulebroecke M; Abi-Saab W; Cooke K; Johns D; Gomez-Mancilla B
    Mov Disord; 2011 Jun; 26(7):1243-50. PubMed ID: 21484867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson's disease.
    Luginger E; Wenning GK; Bösch S; Poewe W
    Mov Disord; 2000 Sep; 15(5):873-8. PubMed ID: 11009193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study.
    Snow BJ; Macdonald L; Mcauley D; Wallis W
    Clin Neuropharmacol; 2000; 23(2):82-5. PubMed ID: 10803797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
    Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
    Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NMDA antagonist memantine improves levodopa-induced dyskinesias and "on-off" phenomena in Parkinson's disease.
    Varanese S; Howard J; Di Rocco A
    Mov Disord; 2010 Mar; 25(4):508-10. PubMed ID: 20014061
    [No Abstract]   [Full Text] [Related]  

  • 13. Glutamate release inhibition ineffective in levodopa-induced motor complications.
    Bara-Jimenez W; Dimitrova TD; Sherzai A; Aksu M; Chase TN
    Mov Disord; 2006 Sep; 21(9):1380-3. PubMed ID: 16758479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
    Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia.
    Vidal EI; Fukushima FB; Valle AP; Villas Boas PJ
    J Am Geriatr Soc; 2013 Jan; 61(1):170-2. PubMed ID: 23311565
    [No Abstract]   [Full Text] [Related]  

  • 16. Low dose quetiapine for drug induced dyskinesias in Parkinson's disease: a double blind cross over study.
    Katzenschlager R; Manson AJ; Evans A; Watt H; Lees AJ
    J Neurol Neurosurg Psychiatry; 2004 Feb; 75(2):295-7. PubMed ID: 14742609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone.
    Rascol O; Barone P; Behari M; Emre M; Giladi N; Olanow CW; Ruzicka E; Bibbiani F; Squillacote D; Patten A; Tolosa E
    Clin Neuropharmacol; 2012; 35(1):15-20. PubMed ID: 22222634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study.
    Moreau C; Delval A; Tiffreau V; Defebvre L; Dujardin K; Duhamel A; Petyt G; Hossein-Foucher C; Blum D; Sablonnière B; Schraen S; Allorge D; Destée A; Bordet R; Devos D
    J Neurol Neurosurg Psychiatry; 2013 May; 84(5):552-5. PubMed ID: 23077087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial.
    Corvol JC; Durif F; Meissner WG; Azulay JP; Haddad R; Guimarães-Costa R; Mariani LL; Cormier-Dequaire F; Thalamas C; Galitzky M; Boraud T; Debilly B; Eusebio A; Houot M; Dellapina E; Chaigneau V; Salis A; Lacomblez L; Benel L; Rascol O;
    Parkinsonism Relat Disord; 2019 Mar; 60():51-56. PubMed ID: 30297210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.